Pages that link to "Q46911236"

The following pages link to Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial (Q46911236):

Displayed 50 items.

• Secukinumab for rheumatology: development and its potential place in therapy (Q26738523) ‎ (← links)
• Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-Analysis (Q26764820) ‎ (← links)
• Profile of secukinumab in the treatment of psoriasis: current perspectives (Q26776303) ‎ (← links)
• Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies (Q26777084) ‎ (← links)
• Old and new treatment targets in axial spondyloarthritis (Q26777906) ‎ (← links)
• Immunopathology of synovitis: from histology to molecular pathways (Q26781647) ‎ (← links)
• Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond (Q26991709) ‎ (← links)
• HLA-B27-Homodimer-Specific Antibody Modulates the Expansion of Pro-Inflammatory T-Cells in HLA-B27 Transgenic Rats (Q27303777) ‎ (← links)
• New targets in psoriatic arthritis (Q28069592) ‎ (← links)
• Secukinumab for ankylosing spondylitis and psoriatic arthritis (Q28071474) ‎ (← links)
• Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions (Q28075766) ‎ (← links)
• Addressing potential prior-data conflict when using informative priors in proof-of-concept studies (Q31036717) ‎ (← links)
• The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis (Q33806334) ‎ (← links)
• Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics (Q33809045) ‎ (← links)
• The flavonoid cyanidin blocks binding of the cytokine interleukin-17A to the IL-17RA subunit to alleviate inflammation in vivo. (Q33922498) ‎ (← links)
• Advances in managing ankylosing spondylitis (Q34201927) ‎ (← links)
• Efficacy of high intensity exercise on disease activity and cardiovascular risk in active axial spondyloarthritis: a randomized controlled pilot study (Q34277511) ‎ (← links)
• IL-17 in severe asthma. Where do we stand? (Q34435370) ‎ (← links)
• Update on ankylosing spondylitis: current concepts in pathogenesis (Q34450732) ‎ (← links)
• Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside. (Q34763844) ‎ (← links)
• Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. (Q34894874) ‎ (← links)
• Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? (Q34937925) ‎ (← links)
• Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis (Q34941693) ‎ (← links)
• Interplay between DNA repair and inflammation, and the link to cancer (Q34989590) ‎ (← links)
• Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity. (Q35068107) ‎ (← links)
• Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis (Q35170882) ‎ (← links)
• T cells as a therapeutic target in SLE. (Q35214963) ‎ (← links)
• Central role of IL-17/Th17 immune responses and the gut microbiota in the pathogenesis of intestinal fibrosis (Q35276739) ‎ (← links)
• Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis (Q35545185) ‎ (← links)
• Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN) (Q35605461) ‎ (← links)
• Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases (Q35614331) ‎ (← links)
• All-Trans Retinoic Acid Improves the Effects of Bone Marrow-Derived Mesenchymal Stem Cells on the Treatment of Ankylosing Spondylitis: An In Vitro Study (Q35739571) ‎ (← links)
• Transplantation of mesenchymal stem cells ameliorates secondary osteoporosis through interleukin-17-impaired functions of recipient bone marrow mesenchymal stem cells in MRL/lpr mice (Q35761240) ‎ (← links)
• Juvenile spondyloarthritis. (Q35800954) ‎ (← links)
• Interleukin-17A promotes the formation of inflammation in the lung tissues of rats with pulmonary fibrosis (Q35871239) ‎ (← links)
• Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis (Q35894857) ‎ (← links)
• Mechanisms of human autoimmunity (Q35899439) ‎ (← links)
• Basic biology and role of interleukin-17 in immunity and inflammation (Q35932948) ‎ (← links)
• CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses (Q36008355) ‎ (← links)
• OsteoRheumatology: a new discipline? (Q36246080) ‎ (← links)
• Elevated serum interleukin-23 levels in ankylosing spondylitis patients and the relationship with disease activity (Q36332633) ‎ (← links)
• Ankylosing spondylitis patients display altered dendritic cell and T cell populations that implicate pathogenic roles for the IL-23 cytokine axis and intestinal inflammation (Q36366157) ‎ (← links)
• Secukinumab. (Q36391509) ‎ (← links)
• Evaluation and Treatment of Childhood Enthesitis-Related Arthritis (Q36498631) ‎ (← links)
• IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients (Q36611562) ‎ (← links)
• Prostaglandin E2-EP4 signaling persistently amplifies CD40-mediated induction of IL-23 p19 expression through canonical and non-canonical NF-κB pathways. (Q36674441) ‎ (← links)
• IL-17-producing γδ T cells enhance bone regeneration (Q36690217) ‎ (← links)
• Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. (Q36715135) ‎ (← links)
• Rebamipide prevents peripheral arthritis and intestinal inflammation by reciprocally regulating Th17/Treg cell imbalance in mice with curdlan-induced spondyloarthritis (Q37045417) ‎ (← links)
• A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis (Q37369583) ‎ (← links)